Laggard Lilly says its CDK 4/6 drug abemaciclib scored in PhIII, while rivals at Novartis, Pfizer sharpen their knives
Just a week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly is announcing that its long-awaited Phase III readout for its rival drug abemaciclib looks good. We won’t get the data until later, but the pharma giant says its MONARCH-2 trial comes with positive progression-free data on advanced hormone-receptor-positive, HER2 negative breast cancer.
Investigators compared abemaciclib combined with fulvestrant to fulvestrant alone. And the data set up an FDA filing sometime in the next three months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.